Stockreport

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy...

Travere Therapeutics, Inc.  (TVTX) 
PDF proteinuria, preservation of kidney function and a generally well-tolerated safety profile compared with active control irbesartan SAN DIEGO, March 11, 2024 (GLOBE NEW [Read more]